Fate Therapeutics Inc (FATE)

[jondoeuk]

ASGCT titles:

Development of Master Multiplexed-Engineered iPSC Bank for Off-the-Shelf Cell-Based Cancer Immunotherapy with Reduced Conditioning Chemotherapy.

Long-Term Stability of iPSC-Derived CD34+ Cell Banks Supports the Sustainable Manufacture of Off-the-Shelf Immunotherapies.

Generation of Human Myeloid Derived Suppressor Cells from Induced Pluripotent Stem Cells (IPSC) for Graft versus Host Disease Therapy.

Long-Term Stability Assessment of IPSC-Derived T and NK Cells Support the Feasibility of Off-the-Shelf Therapeutic Applications.

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody Represent a Novel Therapeutic Strategy to Avoid Host Immune Cell Rejection for Off-the-Shelf Cell-Based Cancer Immunotherapy.

10-Year Stability Assessment of Cryopreserved, Engineered iPSC Banks: Genetic and Phenotypic Characterization.

Robust T-Cell Cellular Reprogramming and Single-Cell Engineering Platform Overcomes Inconsistencies and Heterogeneity Associated with Engineering Primary T Cells.

Development of Next-Generation, Off-the-Shelf CAR T-Cell Immunotherapies for Solid Tumors.

FT536: A First-of-Kind, Off-the-Shelf CAR-iNK Cell Product Candidate for Solid Tumors Designed to Specifically Target MICA/B Stress Proteins and Overcome Mechanisms of Tumor Evasion.